Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.57 - $1.31
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$39.76M
Enterprise Value$18.28M
Total Cash (Recent Filing)$40.11M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding44,663,834
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit9.35
Enterprise Value/Ebitda1.11
Forecast
1Y Price Target
$3.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$25.75M
Bulls Say, Bears Say
Bulls Say
Low LeverageMaterial debt reduction meaningfully lowers default and refinancing risk and preserves optionality. With minimal leverage the company can prioritize R&D, commercialization or partnerships without near-term debt servicing pressure, supporting operational resilience over months.
Sizable Equity BaseA strong equity cushion enhances balance-sheet flexibility to absorb losses and fund strategic initiatives. This sizable equity relative to assets reduces dilution or urgent capital raises risk and supports negotiating power with partners and suppliers over the medium term.
Revenue Recovery / Commercial TractionA large rebound indicates renewed commercial uptake of the approved antifungal, suggesting product-market fit and commercialization capability. If sustained, higher recurring sales can underpin margin recovery and reduce reliance on financing over several quarters.
Bears Say
Negative Free Cash FlowPersistent negative FCF erodes cash reserves and forces dependence on external financing or equity raises. Even with reduced burn versus 2024, ongoing outflows constrain ability to fund commercialization and late-stage trials, creating execution risk over the next 2–6 months.
Highly Volatile RevenueLarge year-to-year swings show revenue is inconsistent and may depend on episodic events or one-off factors. This undermines forecasting, partner confidence and investment planning, making sustained growth and margin improvement uncertain absent clear commercial stability.
Persistent UnprofitabilityDeep negative margins and negative EBITDA indicate the business is not yet self-sustaining. Continued losses will pressure equity and limit reinvestment capacity; unless margins improve through higher sales or cost reductions, profitability risks persist over the medium term.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.56 and its highest was $1.31 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $39.76M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is May 18, 2026 which is in 66 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Mar 04, 2026. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.127 by $0.123.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.12.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 44,663,834 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.25 in its last earnings report, beating expectations of $0.127. Following the earnings report the stock price went up 2.194%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (354.55% Upside)
$3.00 (354.55% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-19.05%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$3.00
▲(354.55% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
6.31% Insiders
13.39% Mutual Funds
6.27% Other Institutional Investors
70.09% Public Companies and
Individual Investors